Conexeu Sciences Targets Q1 2027 with FDA 510(k) Submission for Wound Care Device
What happened
Conexeu Sciences, a preclinical-stage medical device company, is preparing for its planned U.S. Food and Drug Administration (FDA) 510(k) premarket notification. The submission concerns Ten Minute Tissue™, the company's lead candidate for a wound care device. Conexeu is also advancing its investigational tissue-restoration platform, CXU™. The company stated it remains on track to make the submission during the first calendar quarter of 2027.
From manilatimes.net
Why it matters
The company is currently conducting manufacturing, testing, and preclinical work to support the regulatory filing. Management views manufacturing scale-up as a critical stage for transitioning the product from a development-stage candidate toward a potential commercial product.
From manilatimes.net
Who's involved
- FDAThe U.S. Food and Drug Administration is the target of the company's regulatory submission.
Keep exploring
The entities involved
Related events
- Providence Medical Technology, Inc. received 510(k) clearance from the FDA and plans to showcase its system at the Henry B. González Convention Center.
- Philips received FDA 510(k) clearance for a sensor.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Cogent Biosciences plans to submit an NDA to the FDA, with Andrew Robbins as President and CEO.